Abstract
Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanisms of death in Chagas heart disease. The impact of specific etiologic treatment on the prognosis of patients with chronic Chagas heart disease is very limited regardless of the presence or absence of heart failure. Patients with symptomatic Chagas heart disease present serum selenium (Se) levels lower than patients without Chagas heart disease. Moreover, Se supplementation in animal models showed promising results. The aim of this trial is to estimate the effect of Se treatment on prevention of heart disease progression in patients with Chagas cardiomyopathy. However, we had to introduce some protocol modifications in order to keep trial feasibility, as follows: the primary outcome was restricted to left ventricular ejection fraction as a continuous variable, excluding disease progression; the follow-up period was decreased from 5 years to 1 year, an adjustment that might increase the participation rate of our study; the superior age limit was increased from 65 to 75 years; and diabetes mellitus was no longer considered an exclusion criterion. All of these protocol modifications were extensively debated by the research team enrolled in the design, recruitment and conduction of the clinical trial to guarantee a high scientific quality.Trial registrationClinical Trials.gov, NCT00875173. Registered on 20 October 2008.
Highlights
Chagas disease is an endemic zoonosis caused by the protozoan parasite Trypanosoma cruzi
In 2014, we proposed the Selenium Treatment and Chagasic Cardiomyopathy (STCC) study aiming to show superiority of treatment with a daily fixed dose of 100 μg of sodium selenite for 1 year during a 5-year follow-up thereafter [6]
Protocol update The STCC trial is a superiority, double-blind, placebo-controlled, randomized clinical trial aiming to investigate the efficacy of selenium supplementation in patients with Chagas cardiomyopathy
Summary
Chagas disease is an endemic zoonosis caused by the protozoan parasite Trypanosoma cruzi. * Correspondence: marcelo.holanda@ini.fiocruz.br 1Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil Full list of author information is available at the end of the article for high morbidity and mortality [3,4,5]. The original protocol included left ventricular ejection fraction (LVEF) as a continuous variable and disease progression as the primary outcome.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
